专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005123778A2 SOLUBLE ZCYTOR14, ANTI-ZCYTOR14 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 审中-公开
标题翻译：可溶性ZCYTOR14抗体ZIYTOR14抗体和结合合作伙伴及其使用方法
公开(公告)号：WO2005123778A2
公开(公告)日：2005-12-29
申请号：PCT/US2005/020521
申请日：2005-06-10
申请人： ZYMOGENETICS, INC. , PRESNELL, Scott, R. , BURKHEAD, Steven, K. , LEVIN, Steven, D. , KUESTNER, Rolf, E. , GAO, Zeren , JASPERS, Stephen, R. , BILLSBOROUGH, Janine
发明人： PRESNELL, Scott, R. , BURKHEAD, Steven, K. , LEVIN, Steven, D. , KUESTNER, Rolf, E. , GAO, Zeren , JASPERS, Stephen, R. , BILLSBOROUGH, Janine
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/7155 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.
摘要翻译：本发明涉及阻断，抑制，减少，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者多肽分子的活性。 IL-17A和IL-17F是涉及炎症过程和人类疾病的细胞因子。 ZcytoR14是IL-17A和IL-17F的常见受体。本发明包括可溶性ZcytoR14，抗ZcytoR14抗体和结合配偶体，以及使用这些可溶性受体，抗体和结合配偶体拮抗IL-17F，IL-17A或IL-17A和IL-17F两者的方法。

2. 发明申请

WO2005051994A3 ZTNF11, A TUMOR NECROSIS FACTOR 审中-公开
标题翻译： ZTNF11，肿瘤坏死因子
公开(公告)号：WO2005051994A3
公开(公告)日：2005-09-09
申请号：PCT/US2004039210
申请日：2004-11-22
申请人： ZYMOGENETICS INC , GAO ZEREN , SHEPPARD PAUL O , FOX BRIAN A , HOLLOWAY JAMES L , JASPERS STEPHEN R
发明人： GAO ZEREN , SHEPPARD PAUL O , FOX BRIAN A , HOLLOWAY JAMES L , JASPERS STEPHEN R
IPC分类号： A61K38/00 , C07H21/04 , C07K14/525 , C07K16/24 , C07K16/28 , C12P21/02 , C12N15/28 , C07K16/18
CPC分类号： C07K16/2875 , A61K38/00 , C07K14/525 , C07K2317/34
摘要： Novel tumor necrosis factor ligand polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides may be used within methods relating to immune response, and may also be used in the development of immuno-regulatory therapeutics. Also provided are antibodies, binding proteins, agonists and antagonists of the ligand polypeptides.
摘要翻译：公开了新型肿瘤坏死因子配体多肽，编码多肽的多核苷酸，以及相关的组合物和方法。多肽可用于与免疫应答相关的方法中，并且也可用于开发免疫调节治疗。还提供了配体多肽的抗体，结合蛋白，激动剂和拮抗剂。

3. 发明申请

WO2005058952A3 ZTNF13, A TUMOR NECROSIS FACTOR 审中-公开
标题翻译： ZTNF13，肿瘤坏死因子
公开(公告)号：WO2005058952A3
公开(公告)日：2005-08-18
申请号：PCT/US2004042493
申请日：2004-12-16
申请人： ZYMOGENETICS INC , GAO ZEREN , SHEPPARD PAUL O , FOX BRIAN A , HOLLOWAY JAMES L , JASPERS STEPHEN R , APPLEBY MARK W
发明人： GAO ZEREN , SHEPPARD PAUL O , FOX BRIAN A , HOLLOWAY JAMES L , JASPERS STEPHEN R , APPLEBY MARK W
IPC分类号： C07H21/04 , C07K14/525 , C07K14/705 , C07K16/24 , C07K16/28 , C12P21/02 , C12P21/06 , C12Q1/68 , C07K16/18 , C12N5/10 , C12N15/12
CPC分类号： C07K14/525 , C07K16/2875 , C07K2317/34
摘要： Tumor necrosis factor ligand polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides may be used within methods relating to immune response, and may also be used in the development of immuno-regulatory therapeutics. Also provided are antibodies, binding proteins, agonists and antagonists of the ligand polypeptides.
摘要翻译：公开了肿瘤坏死因子配体多肽，编码多肽的多核苷酸，以及相关的组合物和方法。多肽可以在与免疫应答有关的方法中使用，并且还可用于开发免疫调节治疗剂。还提供了配体多肽的抗体，结合蛋白，激动剂和拮抗剂。

4. 发明申请

WO2010055366A4 ANTI-HUMAN IL-21 MONOCLONAL ANTIBODIES 审中-公开
标题翻译：抗人IL-21单克隆抗体
公开(公告)号：WO2010055366A4
公开(公告)日：2012-08-16
申请号：PCT/IB2008005011
申请日：2008-12-08
申请人： ZYMOGENETICS INC , JASPERS STEPHEN R , RIXON MARK W , DILLON STACEY R , RAMSDELL FREDERICK J , KREJSA CECILE M , YI EUGENE C
发明人： JASPERS STEPHEN R , RIXON MARK W , DILLON STACEY R , RAMSDELL FREDERICK J , KREJSA CECILE M , YI EUGENE C
IPC分类号： C07K16/24 , A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , Y10S530/809
摘要： Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells, TH cells or TH17 cells.
摘要翻译：提出人抗人IL-21单克隆抗体和产生它们的杂交瘤。这些抗体中的某些具有结合天然人IL-21，人IL-21的突变重组IL-21蛋白和/或肽区的能力。这些人抗IL-21抗体可用于治疗自身免疫性和炎性疾病，特别是由T滤泡辅助细胞，B细胞，TH细胞或TH17细胞介导的疾病。

5. 发明申请

WO2007111714B1 IL-21 ANTAGONISTS 审中-公开
标题翻译： IL-21拮抗剂
公开(公告)号：WO2007111714B1
公开(公告)日：2008-05-02
申请号：PCT/US2006061277
申请日：2006-11-28
申请人： ZYMOGENETICS INC , SIVAKUMAR PALLAVUR V , JASPERS STEPHEN R
发明人： SIVAKUMAR PALLAVUR V , JASPERS STEPHEN R
IPC分类号： C07K16/24 , A61K39/00 , C07K14/54
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2319/30 , Y10S530/809
摘要： Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.
摘要翻译：鉴定结合IL-21蛋白的单克隆抗体。这些抗体用于鉴定结合中和IL-21活性的IL-21蛋白的区域。描述了杂交瘤和产生抗IL-21单克隆抗体的方法。单克隆抗体可用于治疗IL-21介导的疾病，其可能包括自身免疫性和炎性疾病如胰腺炎，I型糖尿病（IDDM），格雷夫斯病，炎性肠病（IBD），克罗恩病，溃疡性结肠炎，肠易激综合征综合征，多发性硬化症，类风湿性关节炎，憩室病，系统性红斑狼疮，牛皮癣，强直性脊柱炎，硬皮病，系统性硬化症，银屑病关节炎，骨关节炎，特应性皮炎，白癜风，移植物抗宿主病（GVHD），皮肤T细胞淋巴瘤，干燥综合征，肾小球肾炎，IgA肾病，移植物宿主病，移植排斥反应，特应性皮炎，抗磷脂综合征，哮喘和其他自身免疫性疾病。

6. 发明申请

WO2007106769A2 ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME 审中-公开
标题翻译：与IL-17A和IL-17F两个结合的抗体及其使用方法
公开(公告)号：WO2007106769A2
公开(公告)日：2007-09-20
申请号：PCT/US2007063787
申请日：2007-03-12
申请人： ZYMOGENETICS INC , JASPERS STEPHEN R , PRESNELL SCOTT R , RIXON MARK W , LEVIN STEVEN D
发明人： JASPERS STEPHEN R , PRESNELL SCOTT R , RIXON MARK W , LEVIN STEVEN D
CPC分类号： C07K16/468 , A61K2039/505 , C07K16/244 , C07K2317/20 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/76
摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
摘要翻译：本发明涉及阻断，抑制，减少，拮抗或中和IL-17A和IL-17F的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。本发明包括结合IL-17A和IL-17F的抗体以及在炎症中使用它们的方法。

7. 发明申请

WO2005058957A3 ZTNF 12, A TUMOR NECROSIS FACTOR 审中-公开
标题翻译： ZTNF 12，肿瘤坏死因子
公开(公告)号：WO2005058957A3
公开(公告)日：2005-09-09
申请号：PCT/US2004042487
申请日：2004-12-15
申请人： ZYMOGENETICS INC , GAO ZEREN , SHEPPARD PAUL O , FOX BRIAN A , HOLLOWAY JAMES L , JASPERS STEPHEN R
发明人： GAO ZEREN , SHEPPARD PAUL O , FOX BRIAN A , HOLLOWAY JAMES L , JASPERS STEPHEN R
IPC分类号： C07H21/04 , C07K14/525 , C07K14/715 , C07K16/24 , C12N15/09 , C12P21/02 , C12Q1/68 , G01N33/68 , C07K16/28 , C12N5/10
CPC分类号： C07K14/525 , A61K2039/505 , C07K14/7151 , C07K16/241 , C07K2317/34 , C07K2319/30 , C12Q1/6883 , C12Q2600/158 , G01N33/6863 , G01N2500/00
摘要： Novel tumor necrosis factor ligand polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides may be used within methods relating to immune response, and may also be used in the development of immuno-regulatory therapeutics. Also provided are antibodies, binding proteins, agonists and antagonists of the ligand polypeptides.
摘要翻译：公开了新的肿瘤坏死因子配体多肽，编码该多肽的多核苷酸以及相关的组合物和方法。多肽可以在与免疫应答有关的方法中使用，并且也可以用于免疫调节治疗剂的开发中。还提供了配体多肽的抗体，结合蛋白，激动剂和拮抗剂。

8. 发明申请

WO2002072607A2 SOLUBLE HETERODIMERIC CYTOKINE RECEPTOR 审中-公开
标题翻译：可溶性细胞因子受体
公开(公告)号：WO2002072607A2
公开(公告)日：2002-09-19
申请号：PCT/US2002/007214
申请日：2002-03-07
申请人： ZYMOGENETICS, INC. , CHANDRASEKHER, Yasmin, A. , NOVAK, Julia, E. , FOSTER, Donald, C. , XU, Wenfeng , JASPERS, Stephen, R.
发明人： CHANDRASEKHER, Yasmin, A. , NOVAK, Julia, E. , FOSTER, Donald, C. , XU, Wenfeng , JASPERS, Stephen, R.
IPC分类号： C07K
CPC分类号： C07K14/7155 , C07K2319/00
摘要： A soluble receptor that binds to IL-20 having two polypeptide subunits, IL-22R and IL-20RB. The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
摘要翻译：结合具有两个多肽亚单位IL-22R和IL-20RB的IL-20的可溶性受体。两个亚基优选连接在一起。在一个实施方案中，一个亚基与免疫球蛋白的轻链的恒定区融合，另一个亚基与免疫球蛋白的重链的恒定区融合。轻链和重链通过二硫键连接。

9. 发明申请

WO2010055366A3 ANTI-HUMAN IL-21 MONOCLONAL ANTIBODIES 审中-公开
标题翻译：抗人IL-21单克隆抗体
公开(公告)号：WO2010055366A3
公开(公告)日：2010-10-21
申请号：PCT/IB2008005011
申请日：2008-12-08
申请人： ZYMOGENETICS INC , JASPERS STEPHEN R , RIXON MARK W , DILLON STACEY R , RAMSDELL FREDERICK J , KREJSA CECILE M , YI EUGENE C
发明人： JASPERS STEPHEN R , RIXON MARK W , DILLON STACEY R , RAMSDELL FREDERICK J , KREJSA CECILE M , YI EUGENE C
IPC分类号： C07K16/24 , A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , Y10S530/809
摘要： Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells, TH cells or TH17 cells.
摘要翻译：提出人抗人IL-21单克隆抗体和产生它们的杂交瘤。这些抗体中的某些具有结合天然人IL-21，人IL-21的突变重组IL-21蛋白和/或肽区的能力。这些人抗IL-21抗体可用于治疗自身免疫性和炎性疾病，特别是由T滤泡辅助细胞，B细胞，TH细胞或TH17细胞介导的疾病。

10. 发明申请

WO2008133684A8 ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME 审中-公开
公开(公告)号：WO2008133684A8
公开(公告)日：2008-11-06
申请号：PCT/US2007/067637
申请日：2007-04-27
申请人： ZYMOGENETICS, INC. , JASPERS, Stephen, R. , PRESNELL, Scott, R. , RIXON, Mark, W. , LEVIN, Steven, D. , HUBER, Monica
发明人： JASPERS, Stephen, R. , PRESNELL, Scott, R. , RIXON, Mark, W. , LEVIN, Steven, D. , HUBER, Monica
IPC分类号： C07K16/24 , C12N5/18 , A61K39/395 , A61P35/00 , A61P37/06 , A61P31/00
摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, an methods of using the same in inflammation.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式